生物制药公司Akebia Therapeutics（纳斯达克股票代码：AKBA）今日盘前大跌24.65%，股价遭遇重创。这一显著跌幅主要源于公司昨日宣布的新股发行计划，引发了投资者对潜在股权稀释的担忧。
据报道，Akebia Therapeutics已开始筹划股票发行，以寻求新的融资。尽管具体的发行规模尚未披露，但公司已委任Leerink Partners和Piper Sandler作为此次发行的联合账簿管理人。这一融资举措可能会稀释现有股东的股权，因此引发了市场的强烈负面反应。值得注意的是，在此消息公布之前，AKBA股价曾连续四个交易日上涨，累计涨幅高达68%，周三常规交易时段更是上涨11.4%收于2.84美元。
尽管股价出现大幅下跌，但Akebia Therapeutics的业务前景似乎仍然积极。公司此前预计其贫血药物Vafseo在第一季度将实现1000万至1100万美元的净产品收入，显示了公司核心产品的市场潜力。然而，新股发行计划的公布暂时盖过了这一利好因素。随着更多关于股票发行的细节公布，市场将密切关注Akebia Therapeutics的后续发展，特别是其在肾脏疾病治疗领域的进展。投资者需要权衡公司的长期发展潜力与短期股权稀释风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.